CO.DON AG: Repeat GMP certification successfully received for the Teltow site

Berlin / Teltow / Leipzig, 23 March 2020 - The LAVG Brandenburg (State Office for Occupational Health and Safety, Consumer Protection and Health) again confirmed that CO.DON AG's Teltow site was GMP-compliant. GMP - Good Manufacturing Practice - is a binding international standard to ensure the highest safety and quality in pharmaceutical production processes.

After a full inspection covering three days, in her final meeting the Chief Inspector specifically mentioned the excellent preparation and great motivation of all the staff at CO.DON AG.

The Executive Board and the management of the Teltow site join the managers across the company in thanking all the employees in Teltow and Berlin for this great team achievement.

CO.DON sees the certification standards as part of a value chain that links the entire company and culminates in the optimal fulfilment of all customer requirements. Obtaining certification confirms the high quality standard the company achieves with its products and services.

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 15,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). At its site in Leipzig CO.DON has built one of the world's largest and most modern plants for the industrial-scale production and contract manufacturing of human cells. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Tilmann Bur.
Further information is available from

 

Contact

Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)30 240352330
F: +49 (0)30 240352309
E: